Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Issue 3 (March 2020)

• Record Type: Journal Article
• Authors: Haghnejad, Vincent; Le Berre, Catherine; Dominique, Yoann; Zallot, Camille; Guillemin, Francis; Peyrin-Biroulet, Laurent
• Is Part Of: Digestive and liver disease. Volume 52:Issue 3(2020)
• Page Start: 281
• Page End: 288
• Publication Date: 2020-03
• Subjects: Crohn's disease -- CT-P13 -- Patient education -- Ulcerative colitis; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2019.09.012
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: To lighten the burden on health-care spending, switching from the infliximab originator to a biosimilar in patients with inflammatory bowel disease (IBD) is advocated. However, the uptake of biosimilars lacks initiatives aimed at educating patients. Aims: To explore the impact of a gastroenterologist's interview on IBD patients' acceptance for switching from infliximab bio-originator Remicade® to its biosimilar CT-P13 Inflectra®. Methods: After the interview of 138 included patients, 120 properly responded to a self-administered questionnaire to collect consent about the switch and relevant data. French national IBD patients' association (Association François Aupetit) provided an information sheet on biosimilars. Results: 93 (67.0%) out of 138 and 82 (68.3%) out of 120 patients switched treatment. 114 (79.8%) had never heard about biosimilars. Paradoxically, having heard about biosimilars was associated with a poorer chance to switch (Odds Ratio OR [95% CI] = 0.13 [0.02–0.72]). On the contrary, the more satisfied about generics, the more patients accepted the switch (OR [95% CI] = 1.31 [1.01–1.69]). There were 1.47 (Relative Risk RR [95% CI] = 1.47 [1.07–2.01]) times more chance to agree to the switch if the interview modified the patient's opinion on biosimilars. Conclusion: This study confirms that an organized information provided to the patient is a contributive way to enhance patient's acceptance of biosimilars in IBD.